Circulating tumour DNA testing is here - what pathologists need to know.
Recently updated guidelines indicate that molecular testing can be performed on circulating tumour DNA (ctDNA) to rule in EGFR mutation in patients with lung adenocarcinoma who are treatment-naïve or showed progression on first- or secondgeneration tyrosine kinase inhibitors. Pathologists may be ask...
| Published in: | Canadian Journal of Pathology Vol. 12; no. 2; pp. 24 - 30 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Published: |
Canadian Association of Pathologists
May2020
|
| Online Access: | View this record in EBSCOhost |